Protocol Ledger

NCT03303066 · Phase II/III · COMPLETED

Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)

Interventional Phase II/III clinical trial protocol NCT03303066 sponsored by Kyntra Bio in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-06-06 Enrollment: 43 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03303066
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)43 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03303066
Protocol FieldVerified Registry Value
NCT IdentifierNCT03303066
Consolidated Lead SponsorKyntra Bio
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment43 participants (ACTUAL)
Registered Start Date2018-06-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI